Savard Corey, Epps Gregory, Ad Voichita Bar, Curry Joseph, Evans James J, Farrell Christopher J, Nyquist Gurston, Luginbuhl Adam
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, United States.
Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, United States.
J Neurol Surg Rep. 2019 Apr;80(2):e23-e26. doi: 10.1055/s-0039-1687848. Epub 2019 Apr 9.
Recurrent malignancy of the skull base poses a treatment challenge due to a lack of treatment options and potential for damage to surrounding structures. Case report of two patients with recurrent nasopharyngeal carcinoma (NPC) of skull base previously treated with adjuvant chemoradiotherapy using intensity-modulated radiation therapy (IMRT). In both cases, the recurrent tumor was treated with endoscopic surgical resection and intraoperative cesium-131 (Cs-131) interstitial brachytherapy (IBT). Total dose delivered to tumor bed was 57 and 60 Gy, respectively. With a half- life of 9 days, the majority of the radiation dose had been delivered within the first 40 days following implant and there have been no treatment-related complications reported. Intraoperative Cs-131 IBT is a feasible adjuvant treatment option for patients with recurrent malignancies of the skull base. These are the first known cases of Cs-131 IBT used for recurrent NPC.
由于缺乏治疗选择以及对周围结构造成损伤的可能性，颅底复发性恶性肿瘤构成了一项治疗挑战。 报告两例先前接受调强放射治疗（IMRT）辅助放化疗的颅底复发性鼻咽癌（NPC）患者的病例。 在这两个病例中，复发性肿瘤均接受了内镜手术切除和术中铯-131（Cs-131）组织间近距离放疗（IBT）。肿瘤床接受的总剂量分别为57 Gy和60 Gy。半衰期为9天，大部分辐射剂量在植入后的前40天内已释放，且未报告与治疗相关的并发症。 术中Cs-131 IBT是颅底复发性恶性肿瘤患者可行的辅助治疗选择。这是已知首例将Cs-131 IBT用于复发性NPC的病例。
